As of October 2026, WADA bans BPC-157, TB-500, MOTS-c and growth hormone releasers such as CJC-1295, ipamorelin and MK-677 at all times, plus any unapproved peptide. Of the 88 compounds staate covers, 27 are named in a WADA class and 24 more fall under S0 because no country has approved them. Semaglutide and tirzepatide are monitored, not banned.
New trials, FDA changes and side-effect reports, written in plain English. Every result says whether it was tested in people or in animals.
Each row gives the WADA section, what the 2026 list says, and the first list that named the peptide. Filter by status, or link to a row by its anchor, such as #bpc-157.
| Peptide | WADA 2026 status | What the list says | First named |
|---|---|---|---|
| BPC-157 | Prohibited, namedS0 | Named as an example of a non-approved substance. A Specified Substance. | 2022 list |
| TB-500 | Prohibited, namedS2.3 | "Thymosin-ß4 and its derivatives e.g. TB-500." A non-Specified Substance. | On the 2021 list or earlier |
| CJC-1295 | Prohibited, namedS2.2.4 | Named as a GHRH analogue, next to CJC-1293. | On the 2021 list or earlier |
| Sermorelin | Prohibited, namedS2.2.4 | Named as a GHRH analogue. | On the 2021 list or earlier |
| Tesamorelin | Prohibited, namedS2.2.4 | Named as a GHRH analogue. Banned even though Egrifta is FDA-approved. | On the 2021 list or earlier |
| Ipamorelin | Prohibited, namedS2.2.4 | Named as a growth hormone secretagogue. | On the 2021 list or earlier |
| MK-677 (ibutamoren) | Prohibited, namedS2.2.4 | Named as "ibutamoren (MK-677)", a growth hormone secretagogue. Not a peptide, but listed with them. | 2024 list |
| GHRP-2 | Prohibited, namedS2.2.4 | Named as "GHRP-2 (pralmorelin)", a GH-releasing peptide. | On the 2021 list or earlier |
| GHRP-6 | Prohibited, namedS2.2.4 | Named as a GH-releasing peptide. | On the 2021 list or earlier |
| Hexarelin | Prohibited, namedS2.2.4 | Named as "examorelin (hexarelin)", a GH-releasing peptide. | On the 2021 list or earlier |
| AOD-9604 | Prohibited, namedS2.2.3 | Named as a growth hormone fragment. | On the 2021 list or earlier |
| HGH Fragment 176-191 | Prohibited, namedS2.2.3 | Named as "hGH 176-191", a growth hormone fragment. | On the 2021 list or earlier |
| IGF-1 LR3 | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." LR3 is an IGF-1 analogue. | On the 2021 list or earlier |
| PEG-MGF | Prohibited, namedS2.3 | "Mechano growth factors (MGFs)." | On the 2021 list or earlier |
| MOTS-c | Prohibited, namedS4.4.1 | Named as an activator of AMP-activated protein kinase (AMPK), a metabolic modulator. | 2025 list |
| Follistatin-344 | Prohibited, namedS4.3 | Named under myostatin inhibitors: "Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)." Gene therapy delivery is separately prohibited under M3.1. | On the 2021 list or earlier |
| IGF-1 DES | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." Des(1-3)IGF-I is an IGF-1 analogue, and anti-doping labs have validated blood tests for it. | On the 2021 list or earlier |
| Thymosin Beta-4 | Prohibited, namedS2.3 | "Thymosin-ß4 and its derivatives e.g. TB-500." The full-length protein is the named substance; TB-500 is listed as one of its derivatives. A non-Specified Substance. | On the 2021 list or earlier |
| Somatropin (HGH) | Prohibited, namedS2.2.3 | "Growth hormone (GH), its analogues and fragments." The weekly analogues lonapegsomatropin, somapacitan and somatrogon are named as examples. A non-Specified Substance. Banned even though every product is FDA-approved. | On the 2021 list or earlier |
| Mecasermin (Increlex) | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." A non-Specified Substance. Banned even though Increlex is FDA-approved. | On the 2021 list or earlier |
| Desmopressin | Prohibited, namedS5 | Named under diuretics and masking agents, prohibited in and out of competition. A Specified Substance. | On the 2021 list or earlier |
| hCG | Prohibited in malesS2.2.1 | "Chorionic gonadotrophin (CG)" under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Kisspeptin-10 | Prohibited in malesS2.2.1 | "Kisspeptin and its agonist analogues" under testosterone-stimulating peptides in males. | 2024 list |
| Gonadorelin | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues" under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Leuprolide (leuprorelin) | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues", naming leuprorelin, under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Triptorelin | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues", naming triptorelin, under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| ARA-290 | Prohibited, by classS2.1.5 | Not named. S2.1.5 bans innate repair receptor agonists, the receptor ARA-290 was designed to act on. No approval anywhere, so S0 would also apply. | Not named |
| Retatrutide | Prohibited under S0S0 | Not named. A drug still in clinical trials, which S0 lists as an example of what it covers. | Not named |
| Cagrilintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Survodutide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Eloralintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| SLU-PP-332 | Prohibited under S0S0 | Not named on the 2026 list. No approval anywhere, so S0 covers it.2027: Named under S4.4.1 from January 1, 2027. | Not named |
| Melanotan-2 | Prohibited under S0S0 | Not named. Never approved by any regulator. | Not named |
| Epitalon | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| KPV | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| LL-37 | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| GHK-Cu | Prohibited under S0S0 | Not named. Injectable research product has no drug approval anywhere. The list does not mention cosmetics. | Not named |
| AHK-Cu | Prohibited under S0S0 | Not named. No drug application has ever been filed for it. | Not named |
| Dihexa | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| FOXO4-DRI | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| P21 (P021) | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| PE-22-28 | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| Pinealon | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| Thymulin | Prohibited under S0S0 | Not named. The synthetic form was tested in the 1980s and never approved. | Not named |
| 5-Amino-1MQ | Prohibited under S0S0 | Not named. Not a peptide, and not approved anywhere. | Not named |
| CagriSema (cagrilintide + semaglutide) | Prohibited under S0S0 | Not named. Its cagrilintide component has no approval anywhere, so S0 covers the combination. Semaglutide alone is not banned. | Not named |
| Amycretin (zenagamtide) | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Petrelintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Pemvidutide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Humanin | Prohibited under S0S0 | Not named. A research peptide with no approval by any regulator for human therapeutic use, which is what S0 covers. | Not named |
| Larazotide | Prohibited under S0S0 | Not named. Never approved anywhere, and its phase 3 development was discontinued in 2022. S0 explicitly covers drugs under clinical development or discontinued. | Not named |
| Semaglutide | Allowed, monitored | Not on the list. In the 2026 Monitoring Program, which tracks use without banning it.2027: Still not banned; still monitored in 2027. | Not named |
| Tirzepatide | Allowed, monitored | Not on the list. In the 2026 Monitoring Program, which tracks use without banning it.2027: Still not banned; still monitored in 2027. | Not named |
| Mazdutide | Not named, approved | Not named. Approved in China in June 2025, and S0 covers only drugs with no approval anywhere. | Not named |
| PT-141 (bremelanotide) | Not named, approved | Not named. FDA-approved as Vyleesi in 2019. | Not named |
| Oxytocin | Not named, approved | Not named. FDA-approved as Pitocin. | Not named |
| Melanotan-1 (afamelanotide) | Not named, approved | Not named. FDA-approved as Scenesse in 2019. | Not named |
| SS-31 (elamipretide) | Not named, approved | Not named. FDA-approved as Forzinity in September 2025. | Not named |
| Thymosin Alpha-1 | Not named, approved | Not named. Approved as Zadaxin in China and other countries for hepatitis B, though not in the US. | Not named |
| Selank | Not named, approved | Not named. Registered as a medicine in Russia (nasal drops). | Not named |
| Semax | Not named, approved | Not named. Sold in Russia as nasal drops with an official label. | Not named |
| Cerebrolysin | Not named, approved | Not named. Authorized as a medicine in Austria, though not registered with the FDA. | Not named |
| VIP (aviptadil) | Not named, approved | Not named. Aviptadil, with phentolamine, is licensed in the UK as Invicorp (marketing authorisation of April 2015). | Not named |
| DSIP | Not named, approved | Not named. Registered in Russia as Deltaran (LP-016126), which contains DSIP with glycine. Approved nowhere else. | Not named |
| Efpeglenatide | Not named, approved | Not named. Approved in South Korea as Eppe in October 2026, and S0 covers only drugs with no approval anywhere. Not on the Monitoring Program, which lists only semaglutide and tirzepatide among GLP-1 drugs. | Not named |
| Liraglutide | Not named, approved | Not named. FDA-approved as Victoza (2010) and Saxenda (2014). Not in the 2026 Monitoring Program, which lists only semaglutide and tirzepatide markers. | Not named |
| Dulaglutide | Not named, approved | Not named. FDA-approved as Trulicity in 2014. Not in the 2026 Monitoring Program, which lists only semaglutide and tirzepatide markers. | Not named |
| Exenatide | Not named, approved | Not named. FDA-approved since 2005 (Byetta); the brands were discontinued in the US in 2024, but generic exenatide is FDA-approved and sold. | Not named |
| Setmelanotide | Not named, approved | Not named. FDA-approved as Imcivree in 2020 and authorized in the EU in 2021. | Not named |
| Teriparatide | Not named, approved | Not named. FDA-approved as Forteo in 2002, with generic versions since 2023. | Not named |
| Abaloparatide | Not named, approved | Not named. FDA-approved as Tymlos in 2017. | Not named |
| Cetrorelix | Not named, approved | Not named. S2.2.1 covers GnRH and its agonist analogues; cetrorelix is a GnRH antagonist. FDA-approved as Cetrotide in 2000. | Not named |
| Khavinson bioregulators | Check firstS0 for most | Not named. Thymalin and Thymogen are registered medicines in Russia; the synthetic organ peptides (Vilon, Cortagen and others) have no drug approval, so S0 covers them. | Not named |
| SNAP-8 | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| NAD+ | Check firstM2.2 | Not a peptide and not named. Any IV infusion or injection over 100 mL in 12 hours is a prohibited method, which covers many NAD+ drips. | Not named |
| Argireline (acetyl hexapeptide-8) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl (palmitoyl pentapeptide-4) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl 3000 | Check first | Not named. A topical cosmetic blend of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl synthe'6 (palmitoyl tripeptide-38) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| SYN-AKE | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics or acetylcholine receptor blockers. | Not named |
| Leuphasyl (pentapeptide-18) | Check first | Not named. A topical cosmetic enkephalin analog, never developed as a drug. S7 is a closed list of named narcotics and does not include it. | Not named |
| Eyeseryl (acetyl tetrapeptide-5) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Melanostatin (nonapeptide-1) | Check first | Not named. A topical cosmetic ingredient that blocks MC1R, never developed as a drug. The list does not mention cosmetics. | Not named |
| Hexapeptide-9 | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Decorinyl (tripeptide-10 citrulline) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Carnosine | Check first | Not named. A dietary supplement and food compound with no drug approval of its own; a zinc-carnosine chelate (polaprezinc) is an approved ulcer drug in Japan. The list does not mention dietary supplements. | Not named |
| Glutathione | Check firstM2.2 | Not named. Approved as an injectable drug in Japan (Tathion), so S0 does not apply. Any IV infusion or injection over 100 mL in 12 hours is a prohibited method, which covers many glutathione drips. | Not named |
| Pramlintide | Check firstS0 possible | Not named. FDA-approved as Symlin in 2005, but every Symlin strength is now listed as discontinued. S0 covers discontinued drugs with no current approval, so ask your anti-doping organization. | Not named |
"Prohibited under S0" means the peptide is not named, but has no approval from any government health authority, which is what S0 bans. "Not named, approved" means the substance is approved as a medicine in at least one country, so S0 does not reach it. That is not a clearance: the S2 classes also cover substances with a similar structure or effect, so a tested athlete should confirm with their anti-doping organization first. The legal side, FDA approval and pharmacy compounding, is on the peptide legal status guide. This table is about sport only and says nothing about whether a peptide works or is safe.
The CSV holds every row with its section, the list wording, the first year named, the 2027 change and the check date.
Staate. "WADA status of peptides: banned in sport table." Last checked October 19, 2026. https://staate.co/peptides/guides/peptides-banned-in-sport/
<iframe src="https://staate.co/embed/peptides-banned-in-sport/" title="WADA status of peptides, tracked by Staate" width="100%" height="640" loading="lazy" style="border:1px solid #d9e4df;border-radius:12px;max-width:100%"></iframe> <p style="font:13px/1.5 sans-serif;margin:6px 0 0">Source: <a href="https://staate.co/peptides/guides/peptides-banned-in-sport/">Staate, WADA status of peptides: banned in sport table</a></p>
Almost every peptide sits in S0 for unapproved drugs, one of five S2 subsections for hormones and growth factors, or S4.4.1 for metabolic modulators. All of them apply in and out of competition, and M2.2 limits IV drips whatever they contain.
| Section | What the list says | Peptides on staate it covers |
|---|---|---|
| S0 Non-approved substances | Any pharmacological substance not covered elsewhere on the list and with no current approval by any government health authority for human therapeutic use. Prohibited at all times. A Specified Substance class. | BPC-157 (named), retatrutide, cagrilintide, survodutide, melanotan-2, epitalon, KPV, LL-37 and other unapproved peptides |
| S2.1.5 Innate repair receptor agonists | Agonists of the innate repair receptor, for example asialo EPO and carbamylated EPO. | ARA-290 (not named) |
| S2.2.1 Testosterone-stimulating peptides in males | Chorionic gonadotrophin, LH, GnRH and its agonist analogues, kisspeptin and its agonist analogues. | hCG, kisspeptin-10 |
| S2.2.3 Growth hormone, analogues and fragments | Names AOD-9604 and hGH 176-191 as growth hormone fragments. | AOD-9604, HGH Fragment 176-191 |
| S2.2.4 Growth hormone releasing factors | GHRH and its analogues, growth hormone secretagogues and their mimetics, GH-releasing peptides. | CJC-1295, sermorelin, tesamorelin, ipamorelin, MK-677, GHRP-2, GHRP-6, hexarelin |
| S2.3 Growth factors and modulators | IGF-1 and its analogues, mechano growth factors, thymosin-ß4 and its derivatives such as TB-500, and other growth factors. | TB-500, IGF-1 LR3, PEG-MGF |
| S4.4.1 Metabolic modulators | AMPK activators, naming AICAR and MOTS-c; PPAR-delta agonists; Rev-erb-alpha agonists. | MOTS-c |
| M2.2 Chemical and physical manipulation | IV infusions or injections of more than 100 mL in total per 12 hours, except in hospital treatment, surgery or clinical tests. | Any IV drip, including NAD+ |
S2 opens with the rule that substances with a similar chemical structure or similar biological effect are also prohibited. Everything in S2 and S4.4 is a non-Specified Substance; everything in S0 is a Specified Substance. USADA says use or possession of a non-Specified Substance carries a default four-year ban.
Usually not. S0 bans "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use."
That sentence covers drugs still in trials, such as retatrutide and survodutide, and research peptides that were never approved anywhere, such as KPV, epitalon and melanotan-2. A "research use only" label is not an approval. The 2026 list names only one peptide in S0, BPC-157, and S0 still reaches the rest.
The reverse case is a peptide approved somewhere and not named. Selank and Semax are sold as medicines in Russia, thymosin alpha-1 is approved as Zadaxin in China, and mazdutide was approved in China in 2025. S0 does not reach these, because each has a government approval.
The examples in S0 now read "designer drugs, peptides, substances approved only for veterinary use". BPC-157 stays the named example.
SLU-PP-332 and SLU-PP-915 join S4.4.1 as metabolic modulators. Under the 2026 list, S0 already covered SLU-PP-332.
Semaglutide and tirzepatide stay off the list and in the Monitoring Program. One study on athletes is running and WADA has started a second.
The growth hormone, testosterone-stimulating and growth factor sections name the same peptides as in 2026.
Regulatory fact, from the WADA release of September 21, 2026 and the 2027 list with changes marked.
Yes. After a whistleblower tip, USADA found that a 46-year-old age-group triathlete had used and possessed BPC-157 and TB-500, and had promoted BPC-157, TB-500, CJC-1295, ipamorelin and tesamorelin on social media, which USADA treated as attempted complicity. USADA first sought five years and cut it to four for an early admission. The four-year ban runs from September 9, 2025, and he lost his results back to June 1, 2024.
Read the USADA release16 rows in the table are marked check first, and the 19 rows marked not named, approved rest on an approval in one or more countries. For any of these, ask your national anti-doping organization before you use the product.
Thymalin and Thymogen are registered medicines in Russia. The synthetic organ-named peptides (Vilon, Cortagen, Cardiogen and others) have no drug approval anywhere, so S0 covers them.
Sold in skin creams and never developed as drugs. The list says nothing about cosmetic ingredients either way.
NAD+ is not named and is not a peptide. The rule that matters is M2.2: more than 100 mL by IV in 12 hours is a prohibited method, whatever is in the bag.
Added an embeddable copy of the table for other sites, with the same rows, check date, status filter and a name search.
Page published. All 88 rows checked against the text of the WADA 2026 Prohibited List, the 2027 list and its explanatory note (published September 21, 2026), the 2026 and 2027 Monitoring Programs, and the 2021 to 2025 lists for the year each peptide was first named.
Related pages: BPC-157, TB-500, MK-677, the muscle growth peptides ranked by evidence, the strength training guide, and peptide warnings by country from the TGA, Health Canada, MHRA and Medsafe. How we label evidence: editorial policy.
We email when the Prohibited List, an FDA rule or a ban case changes what this page says. Daily peptide brief, free, every source linked.